Cite
HARVARD Citation
Kumar, S. et al. (2020). Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet oncology. 21 (10), pp. 1317-1330. [Online].